Summary
Johnson & Johnson reported a solid first quarter for 2014, with worldwide sales reaching $18.1 billion, a 3.5% increase year-over-year. This growth was primarily driven by a robust performance in the Pharmaceutical segment, which saw a 10.8% total sales increase, fueled by strong performances in immunology, infectious diseases, and oncology. The Medical Devices and Diagnostics segment remained flat year-over-year, while the Consumer segment experienced a slight decline. Net earnings for the quarter were $4.7 billion, resulting in diluted EPS of $1.64, a notable increase from the prior year's $1.22. The company generated strong operating cash flow of $3.9 billion, despite significant uses of cash for investing activities, primarily in marketable securities, and financing activities, including dividends and share repurchases. The company also announced plans to divest its Ortho-Clinical Diagnostics business, a significant move that will reshape its business portfolio. Despite ongoing legal challenges, particularly in product liability, Johnson & Johnson maintains a confident outlook, stating that the ultimate outcome of these proceedings is not expected to have a material adverse effect on its financial position.
Financial Highlights
54 data points| Revenue | $18.11B |
| Cost of Revenue | $5.46B |
| Gross Profit | $12.66B |
| SG&A Expenses | $5.18B |
| Operating Income | $5.65B |
| Interest Expense | $136.00M |
| Net Income | $4.73B |
| EPS (Basic) | $1.67 |
| EPS (Diluted) | $1.64 |
| Shares Outstanding (Basic) | 2.83B |
| Shares Outstanding (Diluted) | 2.87B |
Key Highlights
- 1Worldwide sales increased by 3.5% to $18.1 billion, driven by the Pharmaceutical segment's 10.8% growth.
- 2Net earnings rose to $4.7 billion, with diluted EPS reaching $1.64, up from $1.22 in the prior year.
- 3Strong operational cash flow of $3.9 billion was generated, supporting investing and financing activities.
- 4The company announced the planned divestiture of its Ortho-Clinical Diagnostics business for approximately $4.0 billion.
- 5The Pharmaceutical segment showed significant growth, particularly in Immunology, Infectious Diseases, and Oncology therapeutic areas.
- 6Despite a flat performance in Medical Devices and Diagnostics and a slight decline in Consumer sales, overall company performance was positive.
- 7Johnson & Johnson continued to return capital to shareholders through dividends and share repurchases.